Gossamer Bio
GOSS
110 hedge funds and large institutions have $234M invested in Gossamer Bio in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 26 increasing their positions, 31 reducing their positions, and 15 closing their positions.
80% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 15
19% more capital invested
Capital invested by funds: $197M → $234M (+$36.5M)
12% more funds holding
Funds holding: 98 → 110 (+12)
2% more call options, than puts
Call options by funds: $663K | Put options by funds: $650K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7.6% less ownership
Funds ownership: 95.29% → 87.69% (-7.6%)
16% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$2.53M |
| 2 |
Millennium Management
New York
|
+$2.5M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.5M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.44M |
| 5 |
AG
Artal Group
Luxembourg
|
+$1.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$7.49M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.49M |
| 3 |
AC
Armistice Capital
New York
|
-$3.79M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.66M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.49M |
GOSS Hedge Fund Activity: Q1 2024 in Review
110 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q1 2024, worth a combined $234M — up 19% from $197M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new GOSS positions and 15 closed out — a net gain of 12 holders — while 26 added to existing stakes and 31 trimmed.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $2.53M. The largest seller was Morgan Stanley, cutting an estimated $7.49M.
- 110 institutional investors held Gossamer Bio (GOSS) as of Q1 2024, up from 98 in Q4 2023.
- Funds reported $234M of Gossamer Bio stock for Q1 2024, up 19% quarter-over-quarter.
- 27 funds opened new Gossamer Bio positions in Q1 2024 and 15 closed out, a net change of +12 holders.
- The largest Gossamer Bio buyer in Q1 2024 was Laurion Capital Management, an estimated $2.53M added.
- The largest Gossamer Bio seller in Q1 2024 was Morgan Stanley, an estimated $7.49M sold.
Based on aggregated 13F filings for Q1 2024.